Generated by All in One SEO v4.9.3, this is an llms.txt file, used by LLMs to index the site.

# MitoXcel™

First Information-Based AI-Driven Therapeutics

## Sitemaps

- [XML Sitemap](https://mitoxcel.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Low muscle mass, obesity, and cause‑specific mortality in cancer patients: a nationwide cohort study](https://mitoxcel.com/low-muscle-mass-obesity-and-cause-specific-mortality-in-cancer-patients-a-nationwide-cohort-study/)
- [Dr. Kevin Slawin is interviewed about Eos SENOLYTIX and of his discovery of MitoXcel Technology.](https://mitoxcel.com/dr-kevin-slawin-is-interviewed-about-eos-senolytix-and-of-his-discovery-of-mitoxcel-technology/) - Dr. Kevin Slawin is interviewed about Eos SENOLYTIX and of his discovery of MitoXcel Technology. August 12th, 2026 – Kevin Slawin, MD, Founder and CEO, Eos SENOLYTIX Watch Dr. Kevin Slawin as he’s interviewed about Eos SENOLYTIX, the company he founded to address the fundamental causes of aging and tells the remarkable story of his
- [Aged circulating CD8+ T cells and their secreted factors drive cognitive decline](https://mitoxcel.com/aged-circulating-cd8-t-cells-and-their-secreted-factors-drive-cognitive-decline/)
- [Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum](https://mitoxcel.com/eos-senolytix-presents-best-in-class-preclinical-body-composition-data-highlighting-unique-muscle-mass-gains-with-mitoxcel-geropeptide-ptc-2105-at-the-sachs-2nd-annual-obesity-cardiometabol/) - Multi-System Improvements in Healthspan with PTC-2105 Treatment Translate into Associated Significant Increases in Cancer-Specific and Overall Survival HOUSTON, TX — June 5, 2026 — Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and metabolic health by targeting the underlying biological mechanisms of
- [Greater lean-body-mass decline with tirzepatide than semaglutide in routine care revealed by body-composition digital phenotyping](https://mitoxcel.com/greater-lean-body-mass-decline-with-tirzepatide-than-semaglutide-in-routine-care-revealed-by-body-composition-digital-phenotyping/)
- [Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses](https://mitoxcel.com/pulmatrix-picked-for-reverse-merger-with-anti-aging-biotech-weeks-after-cullgen-deal-collapses/) - Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
- [Pulmatrix and Eos merge to advance gerotherapeutics](https://mitoxcel.com/pulmatrix-and-eos-merge-to-advance-gerotherapeutics/) - Pulmatrix and Eos merge to advance gerotherapeutics
- [Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan](https://mitoxcel.com/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-therapies-to-improve-healthspan/) - Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan PR Newswire Release • Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company • $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related disease FRAMINGHAM, MA and HOUSTON, TX — March 26, 2026
- [Sustained visceral fat loss is associated with attenuated brain atrophy and improved cognitive function in late midlife](https://mitoxcel.com/sustained-visceral-fat-loss-is-associated-with-attenuated-brain-atrophy-and-improved-cognitive-function-in-late-midlife/)
- [Oxidative Capacity and Ageing in Human Muscle](https://mitoxcel.com/oxidative-capacity-and-ageing-in-human-muscle/)
- [A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s Disease](https://mitoxcel.com/a-mitochondrial-cascade-hypothesis-for-sporadic-alzheimers-disease/)
- [Ageing Oxidative Stress and Mitochondrial Uncoupling](https://mitoxcel.com/ageing-oxidative-stress-and-mitochondrial-uncoupling/)
- [Reduced Mitochondrial Coupling in vivo Alters Cellular Energetics in Aged Mouse Skeletal Muscle](https://mitoxcel.com/reduced-mitochondrial-coupling-in-vivo-alters-cellular-energetics-in-aged-mouse-skeletal-muscle/)
- [Clearance of p16ink4a-Positive Senescent Cells Delays Ageing-Associated Disorders](https://mitoxcel.com/clearance-of-p16ink4a-positive-senescent-cells-delays-ageing-associated-disorders/)
- [Monitoring Tumorigenesis and Senescence in Vivo With a p16ink4a-Luciferase Model](https://mitoxcel.com/monitoring-tumorigenesis-and-senescence-in-vivo-with-a-p16ink4a-luciferase-model/)
- [p16ink4a Reporter Mice Reveal Age-Promoting Effects of Environmental Toxicants](https://mitoxcel.com/p16ink4a-reporter-mice-reveal-age-promoting-effects-of-environmental-toxicants/)
- [Mitochondria to Motion- Optimizing Oxidative Phosphorylation to Improve Exercise Performance](https://mitoxcel.com/mitochondria-to-motion-optimizing-oxidative-phosphorylation-to-improve-exercise-performance/)
- [Naturally Occurring p16ink4a-Positive Cells Shorten Healthy Lifespan](https://mitoxcel.com/naturally-occurring-p16ink4a-positive-cells-shorten-healthy-lifespan/) -  
- [Targeting Cellular Senescence Prevents Age-Related Bone Loss In Mice](https://mitoxcel.com/targeting-cellular-senescence-prevents-age-related-bone-loss-in-mice/)
- [Clearance of Senescent Glial Cells Prevents Tau-Dependent Pathology and Cognitive Decline](https://mitoxcel.com/clearance-of-senescent-glial-cells-prevents-tau-dependent-pathology-and-cognitive-decline/)
- [DNA Repair Deficiency and Senescence In Concussed Professional Athletes Involved in Contact Sports](https://mitoxcel.com/dna-repair-deficiency-and-senescence-in-concussed-professional-athletes-involved-in-contact-sports/)
- [Targeting Senescent Cells Alleviates Obesity‐Induced Metabolic Dysfunction](https://mitoxcel.com/targeting-senescent-cells-alleviates-obesity‐induced-metabolic-dysfunction/)
- [Old Age Increases Microglial Senescence](https://mitoxcel.com/old-age-increases-microglial-senescence/)
- [SA-Beta Gal Following TBI](https://mitoxcel.com/sabgal-following-tbi/) -  
- [Blast Exposure Leads to Accelerated Senescence in the Rat Brain](https://mitoxcel.com/blast-exposure-leads-to-accelerated-senescence-in-the-rat-brain/)
- [The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer’s Disease and Parkinson’s Disease](https://mitoxcel.com/the-role-of-mitochondria-in-neurodegenerative-diseases-the-lesson-from-alzheimers-disease-and-parkinsons-disease/)
- [Senolytic CAR T Cells Reverse Senescence - Associated Pathologies](https://mitoxcel.com/senolytic-car-t-cells-reverse-senescence-associated-pathologies/)
- [Whole‐Body Senescent Cell Clearance Alleviates Age‐Related Brain Inflammation and Cognitive Impairment In Mice](https://mitoxcel.com/whole‐body-senescent-cell-clearance-alleviates-age‐related-brain-inflammation-and-cognitive-impairment-in-mice/)
- [Cellular Senescence in Traumatic Brain Injury- Evidence and Perspectives](https://mitoxcel.com/cellular-senescence-in-traumatic-brain-injury-evidence-and-perspectives/)
- [Mitochondrial dysfunction in cell senescence and aging](https://mitoxcel.com/mitochondrial-dysfunction-in-cell-senescence-and-aging/)
- [Optogenetic rejuvenation of mitochondrial membrane potential extends C. elegans lifespan](https://mitoxcel.com/optogenetic-rejuvenation-of-mitochondrial-membrane-potential-extends-c-elegans-lifespan/)
- [Apoptotic stress causes mtDNA release during senescence and drives the SASP](https://mitoxcel.com/apoptotic-stress-causes-mtdna-release-during-senescence-and-drives-the-sasp/)
- [Inflammatory Biomarkers for Neurobehavioral Dysregulation In Former American Football Players: Findings from the DIAGNOSE CTE Research Project](https://mitoxcel.com/inflammatory-biomarkers-for-neurobehavioral-dysregulation-in-former-american-football-players-findings-from-the-diagnose-cte-research-project/)
- [Prophylactic and Long-Lasting Efficacy of Senolytic CAR T Cells Against Age-Related Metabolic Dysfunction](https://mitoxcel.com/prophylactic-and-long-lasting-efficacy-of-senolytic-car-t-cells-against-age-related-metabolic-dysfunction/)
- [Plasma metabolomic markers underlying skeletal muscle mitochondria function relationships with cognition and motor function](https://mitoxcel.com/plasma-metabolomic-markers-underlying-skeletal-muscle-mitochondria-function-relationships-with-cognition-and-motor-function/)
- [Senescent Cell Transplantation into the Skin Induces Age-Related Peripheral Dysfunction and Cognitive Decline](https://mitoxcel.com/francoac-senescent-cell-transplantation-into-the-skin-induces-age‐related-peripheral-dysfunction-and-cognitive-decline/)
- [Single Cell and Spatial Transcriptomics Highlight the Interaction of Club-like Cells with Immunosuppressive Myeloid Cells in Prostate Cancer](https://mitoxcel.com/single-cell-and-spatial-transcriptomics-highlight-the-interaction-of-club-like-cells-with-immunosuppressive-myeloid-cells-in-prostate-cancer/)
- [Inhibition Of IL-11 Signalling Extends Mammalian Healthspan and Lifespan](https://mitoxcel.com/inhibition-of-il-11-signalling-extends-mammalian-healthspan-and-lifespan/)
- [Blood-derived mitochondrial DNA copy number is associated with Alzheimer disease, Alzheimer-related biomarkers and serum metabolites](https://mitoxcel.com/blood-derived-mitochondrial-dna-copy-number-is-associated-with-alzheimer-disease-alzheimer-related-biomarkers-and-serum-metabolites/)
- [Autologous Mitochondrial Transplant for Acute Cerebral Ischemia: Phase 1 Trial Results and Review](https://mitoxcel.com/autologous-mitochondrial-transplant-for-acute-cerebral-ischemia-phase-1-trial-results-and-review/)
- [Hepatocellular Senescence Induces Multi-Organ Senescence and Dysfunction via TGF-β](https://mitoxcel.com/hepatocellular-senescence-induces-multi-organ-senescence-and-dysfunction-via-tgf-β/)
- [Higher skeletal muscle mitochondrial oxidative capacity is associated with preserved brain structure up to over a decade](https://mitoxcel.com/higher-skeletal-muscle-mitochondrial-oxidative-capacity-is-associated-with-preserved-brain-structure-up-to-over-a-decade/)
- [Topical ABT-263 (Navitoclax) Treatment Reduces Aged Skin Senescence and Improves Subsequent Wound Healing](https://mitoxcel.com/topical-abt-263-navitoclax-treatment-reduces-aged-skin-senescence-and-improves-subsequent-wound-healing/)
- [Recommendations for Mitochondria Transfer and Transplantation Nomenclature and Characterization](https://mitoxcel.com/recommendations-for-mitochondria-transfer-and-transplantation-nomenclature-and-characterization/)
- [Metabolic Rewiring Caused by Mitochondrial Dysfunction Promotes mTORC1-Dependent Skeletal Aging](https://mitoxcel.com/metabolic-rewiring-caused-by-mitochondrial-dysfunction-promotes-mtorc1-dependent-skeletal-aging/)
- [Muscular Strength and Mortality in Women Aged 63 to 99 Years](https://mitoxcel.com/muscular-strength-and-mortality-in-women-aged-63-to-99-years/)
- [Ponce Aurora Appoints Former Estee Lauder Executive as Chief Commercial Officer Ahead of Longevity Product Launches](https://mitoxcel.com/ponce-aurora-appoints-former-estee-lauder-executive-as-chief-commercial-officer-ahead-of-longevity-product-launches/) - Ponce Aurora is developing consumer products powered by its proprietary MitoXcel™ Technology, the first information- and AI-driven mitochondrial-targeted geropeptides addressing a fundamental cause of aging. Appointment strengthens leadership team to drive market readiness for YUUTH- and MitoX-branded product launches planned for later this year. Callout - “Together, Anna and Hélène anchor a growing leadership team as we strive to build the
- [Unintended risks of sarcopenic obesity during weight-loss interventions in older people](https://mitoxcel.com/unintended-risks-of-sarcopenic-obesity-during-weight-loss-interventions-in-older-people/)
- [Muscle-preserving therapies in the era of pharmacological weight loss](https://mitoxcel.com/muscle-preserving-therapies-in-the-era-of-pharmacological-weight-loss/)
- [Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistance](https://mitoxcel.com/comparative-analysis-of-senolytic-drug-sreveals-mitochondrial-determinants-of-efficacy-and-resistance/)
- [Two‑phase model of ageing in mice for improved identification of age‑related and late life metabolic decline](https://mitoxcel.com/two-phase-model-of-ageing-in-mice-for-improved-identification-of-age-related-and-late-life-metabolic-decline/)
- [Founders Longevity Forum in London](https://mitoxcel.com/founders-longevity-forum-in-london/) - At the Founders Longevity Forum in London on June 10-11, 2024, the company’s pitch deck was presented (then under the name Ponce, now SENOTHERAPEUTIX). The event was covered in a series of LinkedIn posts by the Founders Forum Group. Read More
- [Brent Saunders Appointed as Advisory Board Chairman](https://mitoxcel.com/brent-saunders-appointed-as-chairman-advisory-board/) - Saunders was previously CEO of Allergan, the company that developed and launched Botox™ until the company’s $63 billion acquisition by AbbVie Inc. in 2020 Miami, FL – February 26, 2025 9:00 a.m. Eastern – Eos SENOLYTIX, Inc., a company leveraging the growing scientific knowledge surrounding the aging process to develop “anti-aging” gerotherapeutics that may improve
- [Deep phenotyping and lifetime trajectories reveal limited effects of longevity regulators on the aging process in C57BL/6J mice](https://mitoxcel.com/deep-phenotyping-and-lifetime-trajectories-reveal-limited-effects-of-longevity-regulators-on-the-aging-process-in-c57bl-6j-mice/)
- [Skeletal Muscle Mass as a Mortality Predictor among Nonagenarians and Centenarians: A Prospective Cohort Study](https://mitoxcel.com/skeletal-muscle-mass-as-a-mortality-predictor-among-nonagenarians-and-centenarians-a-prospective-cohort-study/)

## Pages

- [MitoXcel](https://mitoxcel.com/) - MitoXcel - The First Information- and AI-Driven Gerotherapeutics Aimed at an Aging-Specific Target. Because we're not getting any younger.
- [Media Center](https://mitoxcel.com/media-center/) - Media Center All Scientific Publications News Press Releases Investors Low muscle mass, obesity, and cause‑specific mortality in cancer patients: a nationwide cohort study September 5, 2026 Read More » Dr. Kevin Slawin is interviewed about Eos SENOLYTIX and of his discovery of MitoXcel Technology. August 19, 2026 Read More » Aged circulating CD8+ T cells
- [Pipeline](https://mitoxcel.com/pipeline-2/) - Eos SENOLYTIX, Perseus SENOLYTIX and Ponce Aurora clinical candidates, all powered by MitoXcel™ Technology across longevity, oncology and consumer applications.
- [MitoXcel™ AI](https://mitoxcel.com/mitoxcel-ai/) - MitoXcelAI™ analyses a proprietary database of geropeptide candidates to train and refine the predictive design rules that define MitoXcel™ Technology.
- [Science and Technology](https://mitoxcel.com/science-and-technology-2/) - MitoXcel™ geropeptides target the Inner Mitochondrial Membrane Potential via two mechanisms: enhancing mitochondrial efficiency and eliminating senescent cells.
- [Pipeline-OLD](https://mitoxcel.com/pipeline/) - Our Pipeline
- [Corporate Contact](https://mitoxcel.com/corporate-contact/) - Contact Us First name Last name Your email Subject Your message Affiliated with SENOTHERAPEUTIX, Inc. Corporate: 9511 Collins Avenue, #1403 Surfside, FL. 33154 Email: info@senotherapeutix.com
- [TECHNOLOGY](https://mitoxcel.com/technology/) - Senescent Cells: A Validated Anti-Aging Target Cellular senescence is characterized by irreversible cell cycle arrest and a proinflammatory senescence-associated secretory phenotype (SASP), which is a major contributor to aging and age-related diseases Senescent cells accumulate during aging and negatively influence lifespan and promote age-dependent changes in several organs Clearance of senescent cells has been shown
- [Company](https://mitoxcel.com/company/) - Our Vision and Strategy Our vision and strategy is to target what we believe to be a fundamental cause of aging, the decreasing Mitochondrial Membrane Potential (ΔΨm) that occurs in cells as we age. This phenomenon is conserved even in C. elegans nematodes. Through this single target, our peptides drive dual mechanisms of rejuvenation in
- [Events & Presentations](https://mitoxcel.com/events-presentations/) - Events & Presentations Upcoming Presentations Past Presentations Investing in the Age of Longevity Add Your Heading Text Here Add Your Heading Text Here In this longevity-investing focused webinar, Dr. Slawin will be presenting Eos SENOLYTIX, giving a sneak preview of the groundbreaking data he will be presenting in March at the International Conference Read More
- [Form Test](https://mitoxcel.com/form-test/)
- [PrintOrgans OD](https://mitoxcel.com/printorgans-od/) - PrintOrgans On Demand is a Joint Venture collaboration between PrintBio and the Wake Forest Institute for Regenerative Medicine (WFIRM), combining forces to develop 3D printed organs “on demand”. PrintOrgans On Demand brings together two leading teams in the field of regenerative medicine, in a collaborative effort that will combine complimentary areas of expertise in ways
- [Products](https://mitoxcel.com/products/) - Our Products PrintBio has developed unique capabilities, materials and technologies that enable the creation of living tissue implants for therapeutic applications. Leveraging this materials science, regulatory and clinical experience, PrintBio is preparing to launch its first two products that provide physicians with unprecedented capabilities in managing their patients. 3DMatrix™ 3D-printed monofilament bioresorbable surgical mesh (pending
- [Terms of Use](https://mitoxcel.com/terms-of-use/) - Terms of Use Agreement Between User and senothera.wpenginepowered.com and ir.senothera.wpenginepowered.com Welcome to senothera.wpenginepowered.com and ir.senothera.wpenginepowered.com. The senothera.wpenginepowered.com and ir.senothera.wpenginepowered.com website (the “Site”) is comprised of various web pages operated by PrintBio, Inc.. senothera.wpenginepowered.com and ir.senothera.wpenginepowered.com is offered to you conditioned on your acceptance without modification of the terms, conditions, and notices contained herein (the “Terms”).
- [Privacy Policy](https://mitoxcel.com/privacy-policy/) - Privacy Policy Protecting your private information is our priority. This Statement of Privacy applies to PrintBio, Inc. and governs data collection and usage. For the purposes of this Privacy Policy, unless otherwise noted, all references to PrintBio, Inc. include https://senothera.wpenginepowered.com/ and https://ir.senothera.wpenginepowered.com/. PrintBio, Inc. website is an informational website. By using PrintBio, Inc. website, you
- [Patients](https://mitoxcel.com/patients/) - PATIENTS Revolutionizing the standard of care for patients across multiple life changing programs Our Vision Our vision is to repair or replace human tissues and organs, that are individually designed for each patient. We aim to treat a wide range of conditions, from congenital to traumatic, as well as injuries subsequent to degeneration and cancer.

## My Templates

- [Default Kit](https://mitoxcel.com/?elementor_library=default-kit)
- [Investors (MitoXcel)](https://mitoxcel.com/?elementor_library=investors-mitoxcel) - Investors Presentations & videos
- [Elementor Loop Item #782](https://mitoxcel.com/?elementor_library=elementor-loop-item-782-2) - Elementor Loop Item #782 Read More »
- [Elementor Loop Item #782](https://mitoxcel.com/?elementor_library=elementor-loop-item-782) - Elementor Loop Item #782 Add Your Heading Text Here Add Your Heading Text Here Add Your Heading Text Here Add Your Heading Text Here Read More » Read More »
- [Elementor Single Post #790](https://mitoxcel.com/?elementor_library=elementor-single-post-790) - Elementor Single Post #790 PrevPreviousElementor Loop Item #782 NextElementor Loop Item #782Next
- [Elementor Archive #768](https://mitoxcel.com/?elementor_library=elementor-archive-768) - Elementor Archive #768 All Scientific Pubulications News Press Releases All Scientific Pubulications News Press Releases Low muscle mass, obesity, and cause‑specific mortality in cancer patients: a nationwide cohort study September 5, 2026 Read More » Dr. Kevin Slawin is interviewed about Eos SENOLYTIX and of his discovery of MitoXcel Technology. August 19, 2026 Read More

## Events and Presentations

- [SENO-THERAPEUTICS SUMMIT 2025](https://mitoxcel.com/events-and-presentat/seno-therapeutics-summit-2025/) - Phaedon Institute is honored to co-host the 2nd Seno-Therapeutics Summit alongside the 10th Annual ICSA Conference. This landmark gathering will take place September 16th–19th at the prestigious National Research Council (CNR) in Rome, Italy. Bringing together the brightest minds in senescence biology, these premier events will unite world-renowned scientists, industry pioneers, and visionaries, fostering collaboration and innovation to push the
- [International Conference on Frailty and Sarcopenia Research 2025](https://mitoxcel.com/events-and-presentat/international-conference-of-frailty-and-sarcopenia-research-2025/) - "Novel Gerotherapeutic Peptides Alleviate Sarcopenia and Frailty In Naturally Aged Mice By Dual Mechanisms Acting Through a Single Aging-Selective Target"International Conference on Frailty and Sarcopenia Research 2025 - oral communication on the plenary session of the International Conference of Frailty and Sarcopenia Research 2025Plenary Session OC2911:50 a.m. in Toulouse, France, (5:50 A.M. EST) Registration
- [GEROSCIENCE-ICFSR2025 Task Force on Pre-Clinical and Clinical Trials](https://mitoxcel.com/events-and-presentat/geroscience-icfsr2025-task-force-on-pre-clinical-and-clinical-trials/) - “Novel Gerotherapeutic Peptide PTC-2105 Reverses the Aging Phenotype In Naturally Aged Mice” Task Force on Pre-Clinical and Clinical Trials 2025 – oral communication 2:20 – 2:40 P.M. local time (8:20 – 8:40 A.M. EST)
- [Founders Longevity Forum - Singapore](https://mitoxcel.com/events-and-presentat/founders-longevity-forum-singapore/) - Building on the first Founders Longevity Forum held in June in London, at which Dr. Slawin brought our company out of five years of “stealth mode” to present our company publicly for the very first time, Dr. Slawin has now been invited back to attend this second event sponsored by Longevity.Technology and the National University
- [Investing in the Age of Longevity](https://mitoxcel.com/events-and-presentat/investing-in-the-age-of-longevity/) - In this longevity-investing focused webinar, Dr. Slawin will be presenting Eos SENOLYTIX, giving a sneak preview of the groundbreaking data he will be presenting in March at the International Conference on Sarcopenia and Frailty in a plenary presentation in Toulouse, France. Registration
- [Founders Longevity Forum](https://mitoxcel.com/events-and-presentat/founders-longevity-forum/) - At the Founders Longevity Forum in London on June 10-11, 2024, Dr. Slawin brought our company out of five years of “stealth mode” to present our company publicly for the very first time (then under the name Ponce Therapteutics, now renamed SENOTHERAPEUTIX). The event was covered in a series of LinkedIn posts by the Founders

## Categories

- [Uncategorized](https://mitoxcel.com/category/uncategorized/)
- [uPAR-targeted CAR T](https://mitoxcel.com/category/upar-targeted-car-t/)
- [Oncology](https://mitoxcel.com/category/oncology/)
- [Exercise Capacity](https://mitoxcel.com/category/exercise-capacity/)
- [Body Composition](https://mitoxcel.com/category/body-composition/)
- [Sarcopenia/Frailty](https://mitoxcel.com/category/sarcopenia-frailty/)
- [Obesity/Glucose Metabolic Disorders](https://mitoxcel.com/category/obesity-glucose-metabolic-disorders/)
- [p16Ink4a-ATTAC Senolytic Mouse Model](https://mitoxcel.com/category/p16ink4a-attac-senolytic-mouse-model/)
- [Eye](https://mitoxcel.com/category/eye/)
- [Skin](https://mitoxcel.com/category/skin/)
- [Cognitive Disorders](https://mitoxcel.com/category/cognitive-disorders/)
- [Kidney](https://mitoxcel.com/category/kidney/)
- [Heart](https://mitoxcel.com/category/heart/)
- [Lifespan](https://mitoxcel.com/category/lifespan/)
- [Bone/Osteoporosis](https://mitoxcel.com/category/bone-osteoporosis/)
- [p16Ink4a-LUC Reporter Mouse Model](https://mitoxcel.com/category/p16ink4a-luc-reporter-mouse-model/)
- [SASP](https://mitoxcel.com/category/sasp/)
- [mTBI/Concussion](https://mitoxcel.com/category/mtbi-concussion/)
- [Neurodegenerative Disorders](https://mitoxcel.com/category/neurodegenerative-disorders/)
- [Review](https://mitoxcel.com/category/review/)
- [News](https://mitoxcel.com/category/news/)
- [Liver](https://mitoxcel.com/category/liver/)
- [Prostate Cancer](https://mitoxcel.com/category/prostate-cancer/)
- [Mitochondrial Membrane Potential (ΔΨm)](https://mitoxcel.com/category/mitochondrial-membrane-potential-δψm/)
- [Muscle](https://mitoxcel.com/category/muscle/)
- [Healthspan](https://mitoxcel.com/category/healthspan/)
- [Press Releases](https://mitoxcel.com/category/press-releases/)
- [Senescent Cells](https://mitoxcel.com/category/senescent-cells/)
- [Brain](https://mitoxcel.com/category/brain/)
- [Mitochondrial Transplant](https://mitoxcel.com/category/mitochondrial-transplant/)
- [Cartilage](https://mitoxcel.com/category/cartilage/)
- [Osteoarthritis](https://mitoxcel.com/category/osteoarthritis/)
- [Sarcopenic Obesity](https://mitoxcel.com/category/sarcopenic-obesity/)
- [Mitochondria](https://mitoxcel.com/category/mitochondria/)
- [Senolytics](https://mitoxcel.com/category/senolytics/)
- [Immune System](https://mitoxcel.com/category/immune-system/)
- [Investors](https://mitoxcel.com/category/investors/)

## Tags

- [Scientific Pubulications](https://mitoxcel.com/tag/scientific-pubulications/)
- [Press Releases](https://mitoxcel.com/tag/press-releases/)
- [News](https://mitoxcel.com/tag/news/)